AU2002212249A1 - 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives - Google Patents

2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives

Info

Publication number
AU2002212249A1
AU2002212249A1 AU2002212249A AU2002212249A AU2002212249A1 AU 2002212249 A1 AU2002212249 A1 AU 2002212249A1 AU 2002212249 A AU2002212249 A AU 2002212249A AU 2002212249 A AU2002212249 A AU 2002212249A AU 2002212249 A1 AU2002212249 A1 AU 2002212249A1
Authority
AU
Australia
Prior art keywords
pyridin
pyrimidin
tetrahydro
pyrimido
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002212249A
Other versions
AU2002212249B2 (en
AU2002212249B9 (en
Inventor
Antonio Almario Garcia
Thierry Gallet
Adrien Tak Li
Alistair Lochead
Severine Marguerie
Alain Nedelec
Mourad Saady
Philippe Yaiche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Mitsubishi Pharma Corp
Original Assignee
Sanofi Aventis France
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00402410A external-priority patent/EP1184383A1/en
Priority claimed from EP00402412A external-priority patent/EP1184385A1/en
Application filed by Sanofi Aventis France, Mitsubishi Pharma Corp filed Critical Sanofi Aventis France
Priority claimed from PCT/EP2001/010726 external-priority patent/WO2002018386A1/en
Publication of AU2002212249A1 publication Critical patent/AU2002212249A1/en
Assigned to SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATION reassignment SANOFI-AVENTIS Amend patent request/document other than specification (104) Assignors: SANOFI-SYNTHELABO
Publication of AU2002212249B2 publication Critical patent/AU2002212249B2/en
Application granted granted Critical
Publication of AU2002212249B9 publication Critical patent/AU2002212249B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Description

SPECIFICATION
2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1 ,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES
Technical Field
The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3β.
Background Art
GSK3β (glycogen synthase kinase 3β) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. It was initially identified as an enzyme able to phosphorylate and hence inhibit glycogen synthase. It was later recognized that GSK3β was identical to tau protein kinase 1 (TPK1 ), an enzyme that phosphorylates tau protein in epitopes that are also found to be hyperphosphorylated in Alzheimer's disease and in several tauopathies.
Interestingly, protein kinase B (AKT) phosphorylation of GSK3β results in a loss of its kinase activity, and it has been hypothesized that this inhibition may mediate some of the effects of neurotrophic factors. Moreover, phosphorylation by GSK3β of β-catenin, a protein involved in cell survival, results in its degradation by an ubiquitinilation dependent proteasome pathway.
Thus, it appears that inhibition of GSK3β activity may result in neurotrophic activity. Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3β, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax. Recent studies have demonstrated that β-amyloid increases the GSK3β activity and tau protein phosphorylation. Moreover, this hyperphosphorylation as well as the neurotoxic effects of β-amyloid are blocked by lithium chloride and by a GSK3β antisense mRNA. These observations strongly suggest that GSK3β may be the link between the two major pathological processes in Alzheimer's disease: abnormal APP (Amyloid Precursor Protein) processing and tau protein hyperphosphorylation. Although tau hyperphosphorylation results in a destabilization of the neuronal cytoskeleton, the pathological consequences of abnormal GSK3β activity are, most likely, not only due to a pathological phosphorylation of tau protein because, as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors. Moreover, it has been shown that β-amyloid-induced increase in GSK3β activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis.
Altogether these experimental observations indicate that GSK3β may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases. These include, in a non- limiting manner, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma.
In addition GSK3β may find application in the treatment of other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors
Disclosure of the Invention
An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of neurodegenerative diseases such as Alzheimer's disease.
Thus, the inventors of the present invention have identified compounds possessing inhibitory activity against GSK3β. As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.
The present invention thus provides pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof:
(I) wherein:
X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom;
Y represents a bond, an ethenylene group, an ethynylene group, a 1,2- cyclopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfinyl group, a carbonyl group, a nitrogen atom being optionally substituted by a Cι.6 alkyl group, a phenyl or a benzyl group; or a methylene group optionally substituted by one or two groups chosen from a C-i-6 alkyl group, a phenyl group, a hydroxyl group or a C1-4 alkoxy group;
R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C3-6 cycloalkyl group a C alkyl group, a CM alkoxy group, a benzyl group or a halogen atom;
when Y represents a bond, a 1 ,2-cyclopropylene, a methylene group optionally substituted or a carbonyl group then R2 represents a Cι.6 alkyl group, a C 3.6 cycloalkyl group, a C alkylthio group, a CM alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a 5,6,7,8- tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a C1-.6 alkyl group, a methylendioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1--3 halogenated alkyl group, a hydroxyl group, a CM alkoxy group, a nitro, a cyano, an amino, a Cι.5 monoalkylamino group, a C2-10 dialkylamino group, a Cι_6 alkylcarbonylamino group, a C3-10 arylcarbonylamino group, a C alkylsulfonyl group, CM alkylsulfonyloxy group or a phenyl group; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C^ alkyl group, a C3.6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1.3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a Cι.6 alkyl group, a methylendioxy group, a halogen atom, a Cι_2 perhalogenated alkyl group, a Cι_3 halogenated alkyl group, a hydroxyl group, a CM alkoxy group, a nitro, a cyano, an amino, a Cι_5 monoalkylamino group, a C2-10 dialkylamino group, a Cι.6alkylcarbonylamino group, a C6,ιo arylcarbonylamino group, a alkylsulfonyl group, C alkylsulfonyloxy group or a phenyl group;
m represents 1 or 2; and n represents 0 to 3.
According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3β activity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
As further preferred embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives. The present invention further provides an inhibitor of GSK3β activity comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the salts thereof, and the solvates thereof and the hydrates thereof.
According to further aspects of the present invention, there is provided a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3β activity, which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.
As used herein, the Cι_6 alkyl group represents a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n- propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert- butyl group, n-pentyl group, isopentyl group, neopentyl group, 1 ,1-dimethylpropyl group, n-hexyl group, isohexyl group, and the like;
The C3-6 cycloalkyl group represents a cyclic alkyl group having from 3 to 6 carbon atoms;
The CM alkoxy group represents an alkyloxy group having 1 to 4 carbon atoms for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, and the like;
The CM alkylthio group represents an alkylthio group having 1 to 4 carbon atoms for example, methylthio group, ethylthio group, propylthio group, isopropylthio group, butylthio group, isobutylthio group, sec-butylthio group, tert- butylthio group, and the like;
The CM alkylsulfonyl group represents an alkylsulfonyl group having 1 to 4 carbon atoms for example, methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group, isobutylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group, and the like;
The halogen atom represents a fluorine, chlorine, bromine or iodine atom; The C1-2 perhalogenated alkyl group represents an alkyl group wherein all the hydrogen have been substituted by halogen atoms, for example a CF3 or C2F5; The C1-3 halogenated alkyl group represents an alkyl group wherein at least one hydrogen has not been substituted by a halogen atom;
The C1-5 monoalkylamino group represents an amino group substituted by one C1.5 alkyl group, for example, methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, tert-butylamino group, pentylamino group and isopentylamino group;
The C2-10 dialkylamino group represents an amino group substituted by two Cι_5 alkyl groups, for example, dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group and diisopropylamino group; The C1-6 alkylcarbonylamino group represents an amino group substituted by a C|.6acyl group, for example, formyl group, acetyl group, propionyl group, pivaloyl group, butyryl group, isobutyryl group, pentanoyl group, 3-methylbutyryl group and hexanoyl group;
The o, 10 arylcarbonylamino group represents an amino group substituted by a benzoyl group and a naphthoyl group;
The ethenylene, ethynylene and the 1 ,2-cyclopropylene group represents respectively the following groups:
The leaving group represents a group which could be easily cleaved and substituted, such a group may be for example a tosyl, a mesyl, a bromide and the like.
The compounds represented by the aforementioned formula (I) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N- bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N- methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, δ-hydroxylysine, and arginine. The base-addition salts of acidic compounds are prepared by standard procedures well known in the art.
When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.
The acid-addition salts of the basic compounds are prepared by standard procedures well know in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution. The acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions. Although medicinally acceptable salts of the basic compounds are preferred, all acid-addition salts are within the scope of the present invention.
In addition to the pyrimidinone derivatives represented by the aforementioned formula (I) and salts thereof, their solvates and hydrates also fall within the scope of the present invention. The pyrimidinone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidinone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention. Examples of preferred compounds of the present invention are shown in table 1 hereinafter. However, the scope of the present invention is not limited by these compounds.
Preferred compounds of the present invention represented by formula (I) include also:
(1) Compounds wherein R1 represents a 3- or4-pyridyl group and more preferably 4-pyridyl group, which may be substituted by a C1-2 alkyl group, C1.2 alkoxy group or a halogen atom; and/or
(2) Compounds wherein X represents hydrogen atoms, an oxygen atom or a methyl group and a hydrogen atom; and/or
(3) Compounds wherein Y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfinyl group, a carbonyl group, a methylene group optionally substituted or a nitrogen atom being optionally substituted by one or two benzyl group; and/or
(4) R2 represents a CM alkyl group, C1-2 alkylthio group, C1-2 alkoxy group, a trifluoromethyl group, a C5-6 cycloalkyl group, a naphthyl ring, a 5,6,7,8- tetrahydronaphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a thiophene ring; the rings being optionally substituted by 1 to 4 substituents.
More preferred compounds of the present invention represented by formula (I) include also: (1) Compounds wherein R1 represents an unsubstituted 4-pyridyl group; and/or
(2) Compounds wherein R2 represents a CM alkyl group, C1-2 alkylthio group, C1-2 alkoxy group, a trifluoromethyl group, a C5-6 cycloalkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a phenyl ring, a pyridyl ring, an indole ring, a thiophene ring; the rings being optionally substituted by 1 to 4 substituents; and/or
(3) Compounds wherein X represents hydrogen atoms, an oxygen atom or a methyl group and a hydrogen atom; and/or
(4) Compounds wherein Y represents a bond, a ethenylene, a ethynylene, a sulphur atom, an oxygen atom, a carbonyl group, a sulfinyl group, a methylene group optionally substituted by a CM alkyl group and/or a hydroxy group, or a nitrogen atom optionally substituted by one or two benzyl group; and/or
(5) n is 0, 1 or 2. Particularly preferred compounds of the present invention represented by formula (I) include the compounds of table 1 :
I : 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one;
2 : 9-(3-phenylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- ajpyrimidin-4-one; 3 : 9-(2-phenylethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 4 : 9-[3-(1H-indol-3-yl)propyl]-2-pyridin-4-yl-6,7)8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 5 : 9-(2-phenoxyethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 6 : 9-[3-(3,4-methylenedioxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
7 : 9-[2-(2-methoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 8 : 9-[2-(4-fluorophenoxyethyl)]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 9 : 9-[3-(2-chlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 10 : 9-[3-(4-methylphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
I I : 9-[3-(4-trifluoromethylphenyl)propyl]-2-pyridin-4-yl-6,7,8I9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
12 : 9-(4-phenylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/-pyrimido[1 ,2- a]pyrimidin-4-one;
13 : 9-[3-(2-methylphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 14 : 9-[2-(2,5-dimethoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
15 : 9-[2-(2-methoxyphenoxy)ethyl]-2-pyridin-4-yl-6,7,8(9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
16 : 9-[3-(2-methoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
17 : 9-[2-(4-chlorophenoxy)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3-methoxyphenyl)propyl3-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(2-methoxyphenylmethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : θ-p-phenylthioethylJ^-pyridin^-yl-e .δ.θ-tetrahydro^H-pyrimidotl ,2- a]pyrimidin-4-one; : 9-[3-(3,4-dimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3,4,5-trimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7F8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(phenylsulfonyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(3,4-fluorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-phenyIpropanoyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(4-fluorophenyl)propylj-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(2,5-dimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(2,4-dichlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3-fluorophenyl)propylj-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(4-chlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3,3-dimethylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(2-cyclohexylethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one : 9-[3-(pyridin-3-yl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(4-methylsulfonyloxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(3-methylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3,3-diphenylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 1 : 9-[4-(4-methoxypheny butyl3-2-pyridin-4-yl-6,7,8)9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[4-(4-nitrophenyl)butyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(2-fluorophenyl)propyl3-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-phenylprop-2-ynyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-phenylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(2-chloro-4-fluorophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(2-phenyl-2-oxo-ethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-benzyloxypropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-methylthioethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(1-naphthyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(thiophen-2-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(3-trifluoromethylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : θ- -^hiophen-S-y ethylJ^-pyridin^-yl-e .δ.g-tetrahydro^H-pyrimidofl ,2- a]pyrimidin-4-one; : 9-[2-(2-bromophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(4-cyclohexylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one : 9-[2-(3-bromophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(4-tert-butylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(2,4,6-trimethylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-ethoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; - 2 : 9-[2-(2-chloro-6-fluorophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(3-chlorophenyl)ethyl]-2-pyridin-4-yl-6,7(8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(3-methylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-methoxybutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro~4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-cyclohexylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-[di(phenylmethyl)amino]propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(2-phenyl-cyclopropylmethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(3-phenylprop-2-enyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(2-phenyl-2-hydroxypropyl)-2-pyridin-4-yl-6,7I8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(4-fluorophenyl)-3-oxo-propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(4,4,4-trifluorobutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-phenyl-3-oxo-propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-phenyl-3-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3,3,3-trifluoro-2-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : (R)-9-[2-phenyl-2-hydroxyethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : (S)-9-[2-phenyl-2-hydroxyethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[1-methyl-2-oxo-2-phenyl-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[1 -methyl-2-hydroxy-2-phenyl-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4~one 75 : 9-[2-(4-methylphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 76 : 9-[2-(4-chlorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 77 : 9-[2-(4-fluorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 78 : 9-[2-(4-phenylphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 79 : 9-[2-(3-methoxyphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
80 : 9-[2-(2-naphthyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 81 : 9-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphth-2-yl)-2-oxo-ethyl]-2-pyridin-
4-yl-6,7,8,9-tetrahydro-4 -/-pyrimido[1,2-a]pyrimidin-4-one; 82 : 9-[2-(3-methoxy-4,5-methylendioxyphenyl)-2-oxo-1-methylethyl]-2-pyridin-4- yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;
83 : 9-[2-(4-methylphenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
84 : 9-[2-(1 ,1 ,4,4-tetramethyM ,2,3,4-tetrahydronaphth-6-yl)-2-hydroxy-ethyl]-2- pyridin-4-yl-6,7,8,9-tetrahydro-4 -/-pyrimido[1,2-a]pyrimidin-4-one;
85 : 9-[2-(phenylamino)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
86 : 9-[2-(3-chlorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 87 : 9-[2-(3-chlorophenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
88 : 9-[2-(3-fluorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
89 : 9-[2-(3-fluorophenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
And the compounds of table 2 :
1 : 1-[2-(1H-lndol-3-yl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, 2 : 1-[3-(phenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)- one, 3 : 1 -[3-(1 H-indol-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, 14 : 1-[2-(phenyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 /-/)- one, : 1 -[3-(2-methylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[3-(2-methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1 -(4-phenylbutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one, : 1 -[3-(2-chlorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[3-(2,5-dimethoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 )2- a]pyrimidin-5(1 H)-one, : 1-[3-(4-methylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[3-(3-methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2- a]pyrimidin-5(1H)-one, : 1-[3-(3,4,5-trimethoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1 -[2-(4-fluorophenoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[2-(4-chlorophenoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2- a]pyrimidin-5(1 H)-one, : 1 -[3-(2,4-dichlorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[2-(phenylthio)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-ajpyrimidin- 5(1H)-one, : 1-(3-phenylpropanoyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[3-(4-fluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[3-(3,4-difluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-(2-cyclohexylethyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1H)- one, : 1-(3,3-dimethylbutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1H)- one. : 1-(2-phenyl-2-oxo-ethyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, and : (S)-1-(4,4,4-trifluoro-3-hydroxybu γJ)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one. 24 : 1-(4,4,4-trifluoro-but-2-en-1-yl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
25 : 1-[3-(4-trifluoromethylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1/-/)-one,
26 : (R)-1-(4,4,4-trifIuoro-3-hydroxybutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
27 : 1 -[3-(2-fluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, 28 : 1 -[2-(2,5-dimethoxy-phenyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
29 : 1-[2-(phenylsulfonyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one,
30 : 1-(4,4,4-trifluorobutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1H)- one,
31 : 1-[3-(pyridin-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-ajpyrimidin-
5(1H)-one,
32 : 1-[2-(2-methoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin- 33 : 1-[2-(4-chloro-phenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2- a]pyrimidin-5(1 H)-one,
34 : 1-[2-(naphth-2-yl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- ajpyrimidin-5(1 H)-one,
35 : 1 -[2-(3-methoxy-4,5-methylendioxy-phenyl)-2-oxo-1 -methyl-ethyl]-7-pyridin-4- yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one,
36 : 1-[2-(4-phenyl-phenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
37 : 1-[2-(4-methylphenyl)2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, 38 : 1-[2-(5)5,8,8-tetramethyl-5,6I7,8-tetrahydronaphth-2-yl)2-oxo-ethyl3-7-pyridin- 4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one,
39 : 1-[2-(4-fluorophenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
40 : 1-[2-(3-methoxyphenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one.
As a further object, the present invention concerns also methods for preparing the pyrimidin-4-onecompounds representød by the aforementioned formula (I). These compounds can be prepared, for example, according to methods explained below.
Preparation method ι
2-[1 ,2-a]pyrimidin-4-one compounds represented by the aforementioned formula (I) may be prepared according to scheme 1.
Scheme 1 0
(III) (i)
(In the above scheme the definition of R1 , R2, X, Y and n are the same as those already described for compound of formula (I)). 5
The [1 ,2-a]pyrimidin-4-one derivative represented by the above formula (III), wherein R1 is as defined for compound of formula (I), is allowed to react with a base such as sodium hydride, sodium carbonate or potassium carbonate, in a 0 solvent such as Λ/,Λ/-dimethylformamide, Λ/-methylpyrrolidine, N,N- dimethylacetamide or chloroform, at a suitable temperature ranging from 0 to 130°C under ordinary air, and then with a compound of formula (II), wherein R2, Y and n are as defined for compound of formula (I) and L represents a leaving group, to obtain the compound of the aforementioned formula (I). 5
Preferably when X represents hydrogen atoms, L represents a bromide or mesyl group and the reaction is carried out with sodium hydride in N,N- dimethylformamide at a suitable temperature ranging from 70 to 130 °C. Preferably when X represents oxygen atom, L represents a chloride and the reaction is carried out with sodium hydride in chloroform at a suitable temperature ranging from 0 to 70 °C.
Compound of formula (II) is commercially available or may be synthesized according to well-known methods of one skilled in the art.
The compound of formula (III) may be prepared according to the method defined in scheme 2.
Scheme 2
(In the above scheme the definition of R1 is the same as already described.)
According to this method, the 3-ketoester of formula (IV) is allowed to react with a compound 2 of formula (V). The reaction may be carried out in an alcoholic solvent such as ethanol, propanol or isopropanol, in presence of a base such as sodium hydride, sodium carbonate or potassium carbonate, at a suitable temperature ranging from 25°-100°C under ordinary air.
Compound of formula (IV) is commercially available or may be synthesised according to well-known methods of one skilled in the art. For example compounds of formula (IV), wherein R1 represent a pyridyl group optionally substituted by a C 1-4 alkyl group, C alkoxy group or a halogen atom, can be prepared by reacting a nicotinic acid optionally substituted by a CM alkyl group, CM alkoxy group or an halogen, with a malonic acid monoester. The reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1,1'-carbonylbis-1H- imidazole in a solvent such as tetrahydrofuran at a temperature ranging from 20 to 70°C.
Compound of formula (V) may be synthesised according to the method described by Smith and Christensen (J. Org. Chem. 1955, 20, 829).
Alternatively and when Y represents an oxygen atom, X represents hydrogen atoms and R2 represents an aryl or heteroaryl group, compounds of the aforementioned formula (I) may be prepared according to scheme 3.
Scheme 3
ns
(I, Y = O, X = hydrogen atoms) (In the above scheme the definition of R1 is the same as already described.) According to this method, compounds of formula (III), are allowed to react with a base such as sodium hydride or potassium carbonate in a solvent such as Λ/,Λ/-dimethylformamide at a suitable temperature ranging from 70° to 130 °C under ordinary air, then followed by addition compounds of formula (VI), wherein Pg represents a protecting group, preferably a tetrahydropyran, and L represents a leaving group, preferably a bromide. The deprotection is then carried out using methods well known to one skilled in the art, such as for example when the protecting group is a tetrahydropyran group, the deprotection is then carried out in presence of ammonium chloride in a solvent such as methanol at a temperature ranging from 20° to 70°C to give compound of formula (VII). Compounds of formula (I), as defined hereabove, can then be prepared by reacting the compound of formula (VII) with a compound of formula (VIII) using methods well known to one skilled in the art, such as for example in presence of triphenylphosphine and diethylazodicarboxylate as coupling agent in a solvent such tetrahydrofuran at room temperature. r
Compounds of formula (VI) and (VIII) are commercially available or may be synthesised according to well-known methods of one skilled in the art.
In the above reactions, protection or deprotection of a functional group may sometimes be necessary. A suitable protecting group Pg can be chosen depending on the type of a functional group, and a method described in the literature may be applied. Examples of protecting groups, of protection and deprotection methods are given for example in Protective groups in Organic Synthesis Greene et al., 2nd Ed. (John Wiley & Sons, Inc., New York).
The compounds of the present invention have inhibitory activity against GSK3β. Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and^hers traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non- small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus- induced tumors.
The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3β and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (I).
As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the aforementioned substances may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases. The type of pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally. 21 Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1 % by weight to 90% by weight based on the weight of an active ingredient.
Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like. Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.
The dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult. Chemical Examples
The present invention will be explained more specifically with reference to the following general examples, however, the scope of the present invention is not limited to these examples.
Example 1 (Compound N° 7 of table 1)
9-[2-(2-Methoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one (Z)-but-2-enedioate (1:1)
1.1. 2-Pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2-a]ρyrimidin-4-one
A mixture of 8.98g (46.5 mmol) of ethyl 3-(4-pyridyl)-3-oxopropionate and 8.0g (46.5 mmol) of 2-amino tetrahydropyrimidine dihydrochloride (prepared according to J. Org. Chem. 1955, 20, 829.) and 19.3g (139.5 mmol) of potassium carbonate in 60ml of ethanol was heated at reflux temperature during 18 h. The cooled solution was evaporated to removed solvent and the residue was treated with water and extracted with dichloromethane. The extracts were dried and evaporated to give 8.0g (75%) of product as a white powder. Mp : 219 °C.
1.2. 9-[2-(2-Methoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one (Z)-but-2-enedioate (1:1)
A suspension of 0.25g (1.09 mmol) of 2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one in 3ml of anhydrous dimethylformamide was treated with 57mg (1.42 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was heated at 70 °C for 30 min. 0.327g (1.42 mmol) of 1-[2-(methylsulfonyloxy)ethyl]-2-methoxybenzene (prepared according to J. Med. Chem. 1963, 26(1), 42) was added and the reaction mixture was heated at 130 °C during 1 h. The cooled solution was treated with water and extracted with ethyl acetate. The organic phase was dried and evaporated to give crude product, which was purified by silica gel chromatography, eluting with dichloromethane/methanol in the proportions 100/0 to 95/5. The 0.33δg of pure product obtained in the form of free base was dissolved in hot ethanol and treated with 1 equivalent of (Z)-but-2-enedioϊc acid . The cooled solution was filtered to afford 0.325 g (62%) of white solid. Mp : 157-160°C. Example 2 (Compound N° 4 of table 1 )
9-[3-(1H-lndol-3-yl)propyl]-2-pyridin-4-yl-6,7,δI9-tetrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one
2.1. 3-(1H-lndol-3-yl)propanol (J. Med. Chem. (1995), 38(11), 1998)
To a suspension of 4.8g (126.6 mmol) of lithium aluminium hydride in 240ml of diethylether at 0°C was added dropwise 10g (52.δ mmol) of 3-(IH-indol-3- yl)propanoic acid dissolved in 430ml of diethylether and the resulting mixture stirred at room temperature for 1 h.
The reaction mixture was diluted with 100ml of diethylether at 0°C and treated with excess of a saturated aqueous solution of sodium sulfate. Further solid sodium sulfate was added and the organic phase was filtered to remove salts. The solvent was evaporated to dryness to give 9g (96%) of product as an oil.
2.2. 3-(1H-lndol-3-yl)propyl bromide (Chem. Pharm. Bull. (1988), 36(8), 2853)
To a solution of 2g (11.41 mmol) of 3-(1H-indol-3-yl)propanol in 40 ml of dioxane was added at room temperature 5.3g (12.55 mmol) of dibromotriphenylphosphorane and the resulting solution was stirred during 18h.
An excess of cyclohexane was added and the resulting precipitate was filtered and discarded. The solvent was evaporated to dryness to give 2.7g (99%) of product as an oil which was used in the subsequent step without further purification.
2.3. 9-[3-(1H-lndol-3-yl)propyl]-2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one
A suspension of 0.30g (1.31 mmol) of 2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one in δml of anhydrous dimethylformamide was treated with 6δmg (1.44 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was heated at 70°C for 30 min. 0.407g (1.71 mmol) of 3-
(1H-indol-3-yl)propyl bromide was added and the reaction mixture was heated at
130 °C during 1δh.
The cooled solution was treated with water and extracted with ethyl acetate. The organic phase was dried and evaporated to give crude product which was purified by silica gel chromatography, eluting with dichloromethane/methanol/ammonia in the proportions 96/2/0.2 to 90/10/1 to afford 0.3g (59%) of pure product.
Mp : 230-232°C. Example 3 (Compound N° 15 of table 1)
9-(2-(2-Methoxyphenoxyethyl))-2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one (Z)-but-2-enedioate (1:1)
3.1. 9-(2-Hydroxyethyl)-2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one
A suspension of 0.30g (1.31 mmol) of 2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one in 6ml of anhydrous dimethylformamide was treated with 63mg (1.5δ mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was heated at 70 °C for 30 min. 0.329g (1.53 mmol) of 2-(2-bromoethoxy)tetrahydro-2H-pyran was added and the reaction mixture was heated at 130°C during 1h.
The cooled solution was treated with water and extracted with ethyl acetate. The organic phase was dried and evaporated to give an oil, which was dissolved in 2ml of methanol and treated with 0.127g of ammonium chloride. The resulting mixture was heated for 1δh at reflux temperature.
The cooled solution was evaporated to dryness and the residue treated with water and solid potassium carbonate and extracted with dichloromethane. The organic phase was evaporated to give 0.15δg (49%) of product as an oil which was used without further purification.
3.2. 9-(2-(2-Methoxyphenoxyethyl))-2-pyridin-4-yl-6,7,δ,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one (Z)-but-2-enedioate (1:1)
To a solution of 0.146g (0.536 mmol) of 9-(2-hydroxyethyl)-2-pyridin-4-yl-6,7,3,9- tetrahydro-4H-pyrimido[1,2-aJpyrimidin-4-one in 4ml of tetrahydrofuran under argon atmosphere, was added 0.197g (0.75 mmol) of triphenylphosphine, O.OδOg (0.643 mmol) 2-methoxyphenol and 0.131g (0.75 mmol) of diethylazodicarboxylate. The reaction mixture was stirred for 1h. The solvent was evaporated and the residue was treated with water and dilute aqueous hydrochloric acid and washed with diethylether. The aqueous phase was neutralised with solid potassium carbonate and extracted with dichloromethane. Evaporation of the organic phase gave crude product, which was purified by chromatography on silica gel, eluting with dichloromethane/methanol/ammonia in the proportions 95/5/0.5 to give O.OδOg of product in the form of a free base.
Treatment with 1 equivalent of (Z)-but-2-enedioϊc acid in ethanol afforded 0.060g (23%) of product.
Mp : 140-142°C. Example 4 (Compound N° 25 of table 1) 9-[3-Phenylpropanoyl]-2-pyridin-4-yl- 6,7,δ,9-tetrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one
A suspension of 0.2g (0.87 mmol) of 2-pyridin-4-yl-6,7,8,9-tetrahydro-4 - - pyrimido[1 ,2-a]pyrimidin-4-one in 5ml of chloroform was treated with 26mg (1.14 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was stirred at room temperature for 15min and then cooled to 0°C. 0.14δg (0.964 mmol) of 3-phenylpropionyl chloride was added and the reaction mixture was stirred at room temperature during 18h. The reaction mixture was washed with a saturated aqueous solution of ammonium chloride and dried and evaporated. The residue was purified by chromatography on silica gel eluting with dichloromethane/methanol in the proportion 100/0 to 95/5 to afford give 0.120mg (38%) of pure product as a white solid. Mp : 137-140°C.
A list of chemical structures and physical data for compounds of the aforementioned formula (I) illustrating the present invention is given in table 1 and 2. The compounds have been prepared according to the methods of the example.
Example 5 (Compound N° 3 of table 2)
1 -[3-(1 H-lndol-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 /-/)- one
5.1. 7-Pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one
A mixture containing δg (41.4 mmol) of ethyl 3-(4-pyridyl)-3- oxopropionate and 14g (164 mmol) of 4,5-dihydro-1H-imidazol-2-ylamine in 75 ml of ethanol was heated at reflux temperature during 1δ h. The solvent was evaporated and the crude product was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 90/10 to obtain 6.3g of 7-pyridin-4-yl-2,3- dihydroimidazo[1 ,2-a]pyrimidin-5(1H)-one as free base. Mp : 318-320°C 5.2. 3-(1H-lndol-3-yl)propanol (J. Med. Chem. (1995), 38(11), 1998)
To a suspension of 4.8g (126.δ mmol) of lithium aluminium hydride in 240ml of diethylether at 0°C was added dropwise 10g (52.δ mmol) of 3-(1H-indol-3- yl)propanoic acid dissolved in 430ml of diethylether and the resulting mixture stirred at room temperature for 1h.
The reaction mixture was diluted with 100ml of diethylether at 0°C and treated with excess of a saturated aqueous solution of sodium sulfate. Further solid sodium sulfate was added and the organic phase was filtered to remove salts. The solvent was evaporated to dryness to give 9g (9δ%) of product as an oil.
5.3. 3-(1H-lndol-3-yl)propyl bromide (Chem. Pharm. Bull. (19δδ), 36(δ), 2δ53)
To a solution of 2g (11.41 mmol) of 3-(1H-indol-3-yl)propanol in 40 ml of dioxane was added at room temperature 5.3g (12.55 mmol) of dibromotriphenylphosphorane and the resulting solution was stirred during 1δh. An excess of cyclohexane was added and the resulting precipitate was filtered and discarded. The solvent was evaporated to dryness to give 2.7g (99%) of product as an oil which was used in the subsequent step without further purification.
5.4. 1 -[3-(1 H-lndol-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-ajpyrimidin- 5(1H)-one
To a suspension of 0.19g (0.δ9 mmol) of 7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one in 10 ml of anhydrous Λ/,Λ/-dimethylformamide was added 0.135g (0.97 mmol) of potassium carbonate and the resulting mixture was heated at 130°C during 10min. There is added 0.232g (0.97 mmol) of 3-(1H-indol-3- yl)propyl bromide and heating is continued for 3 h. The cooled suspension is treated with water, extracted with ethyl acetate and the organic extracts dried over sodium sulfate. The crude product was purified by chromatography on silica gel eluting with a mixture dichloromethane/methanol/ammonia in the ratio 90/10/1 to afford 0.1 δg of pure product. Mp : 213-220°C. Example 6 (Compound N°16 of table 2)
1 -[2-(Phenylthio)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one hydrochloride (1:1)
To a suspension of 0.2g (0.93 mmol) of 7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one in ml of anhydrous Λ,Λ/-dimethylformamide was added 4δ.5mg (1.21 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was heated at 70°C during 30min. There was added 0.32g (1.49 mmol) of 2-bromoethyl phenyl sulphide and heating was continued at 130°C during 1 h.
Water was added to the cooled mixture and the resulting solution extracted with ethyl acetate. The combined extracts were washed with water and evaporated. The crude product was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol/diethylamine in the proportions 96/2/0.2 to obtain pure compound as free base. The compound was converted to the hydrochloride salt by addition of hydrochloric acid to an isopropylic solution of the free base. There is obtained 0.11g of product as a yellow solid. Mp : 199-202°C
Example 7 (Compound N°14 of table 2)
1-[2-(4-Chlorophenoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin- 5(1H)-one hydrochloride (1:1)
To a suspension of 0.2 g (0.93 mmol) of 7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a7pyrimidin-5(1 H)-one in 5 ml of anhydrous /V,Λ-dimethylformamide was added 4δ.5mg (1.21 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was heated at 70°C for 30 min. 0.351g (1.49 mmol) of 2-(4- chlorophenoxy)ethyl bromide was added and the reaction mixture was heated at 130 °C during 13h. Water was added to the cooled mixture and the resulting solution extracted with ethyl acetate. The combined extracts were washed with water and evaporated. The crude product was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 96/4 to obtain pure compound as free base. The compound was converted to the hydrochloride salt by addition of hydrochloric acid to an ethanolic solution of the free base. There is obtained 0.24g of product as a yellow solid. Mp : 211-213°C Example δ (Compound N°17 of table 2)
1 -[-(3-Phenyl)propanoyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)- one
A suspension of 0.2g (0.93 mmol) of 7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 -/)-one in 5ml of Λ/,Λ/-dimethylformamide was treated with 43mg (1.20 mmol) of sodium hydride (60% suspension in mineral oil) and the resulting mixture was stirred at room temperature for 15min and then cooled to 0°C. 0.251 g (1.49 mmol) of 3-phenylpropionyl chloride was added and the reaction mixture was stirred at room temperature during 1δh.
The reaction mixture was washed with a saturated aqueous solution of ammonium chloride and dried and evaporated. The residue was purified by chromatography on silica gel eluting with dichloromethane/methanol in the proportion 100/0 to 95/5 to afford give 0.2g of pure product as a white solid. Mp : 171-172°C.
In the table, R1 is an unsubstituted 4-pyridyl group, Ph represents a phenyl group, in the column "X", when X represents two hydrogen atoms, only "H" is indicated, and in the column R2 , " " indicates the bond attached to the Y group.
Table 1
(I)
Table 2
Test Example: Inhibitory activity of the medicament of the present invention against GSK3β:
Two different protocols can be used.
In a first protocol : 7.5 μM of prephosphorylated GS1 peptide and 10 μM ATP (containing 300,000 cpm of 33P-ATP) were incubated in 25 mM Tris-HCI, pH 7.5, 0.6 mM DTT, 6 mM MgCI2l 0.6 mM EGTA, 0.05 mg/ml BSA buffer for 1 hour at room temperature in the presence of GSK3beta (total reaction volume : 100 microliters).
In a second protocol : 4.1 μM of prephosphorylated GS1 peptide and 42 μM ATP (containing 260,000 cpm 33P-ATP) were incubated in 80 mM Mes-NaOH, pH 6.5, 1 mM Mg acetate, 0.5 mM EGTA, 5 mM 2-mercaptoethanol, 0.02% Tween 20, 10% glycerol buffer for 2 hours at room temperature in the presence of GSK3beta.
Inhibitors were solubilised in DMSO (final solvent concentration in the reaction medium, 1 %).
The reaction was stopped with 100 microliters of a solution made of 25 g polyphosphoric acid (85% P2O5), 126 ml 85% H3PO4, H2O to 500 ml and then diluted to 1 :100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution described above. Incorporated 33P radioactivity was determined by liquid scintillation spectrometry.
The phosphorylated GS-1 peptide had the following sequence : NH2-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH.
The GSK3β inhibitory activity of the compounds of the present invention are expressed in IC50, and as an illustration the range of IC5o's of the compounds in table 1 is between 2 nanomolar to 1 micromolar concentrations. Formulation Example
(1) Tablets
The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus.
Compound of Example 1 30 mg
Crystalline cellulose 60 mg
Corn starch 100 mg
Lactose 200 mg Magnesium stearate 4 mg
(2) Soft capsules
The ingredients below were mixed by an ordinary method and filled in soft capsules. Compound of Example 1 30 mg
Olive oil 300 mg
Lecithin 20 mg
(1) Parenteral preparations
The ingredients below were mixed by an ordinary method to prepare injections contained in a 1 ml ampoule. Compound of Example 1 3 mg
Sodium chloride 4 mg Distilled water for injection 1 ml
Industrial Applicability
The compounds of the present invention have GSK3β inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3β .

Claims (12)

What is claimed is:
1. A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:
0) wherein:
X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C1--2 alkyl group and a hydrogen atom;
Y represents a bond, an ethenylene group, an ethynylene group, a 1 ,2- cyciopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfinyl group, a carbonyl group, a nitrogen atom being optionally substituted by a Cι.6 alkyl group, a phenyl or a benzyl group; or a methylene group optionally substituted by one or two groups chosen from a Ci-β alkyl group, a phenyl group, a hydroxyl group or a C-1-4 alkoxy group;
R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C3.6 cycloalkyl group a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom;
when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C1.6 alkyl group, a C 3-6 cycloalkyl group, a C1.4 alkylthio group, a C1--4 alkoxy group, a C1.2 perhalogenated alkyl group, a C1..3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a Cι.6 alkyl group, a methylendioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a Cι_3 halogenated alkyl group, a hydroxyl group, a C -4 alkoxy group, a nitro, a cyano, an amino, a C1-.5 monoalkylamino group, a C2-10 dialkylamino group, a C1-6 alkylcarbonylamino group, a Cβ,ιo arylcarbonylamino group, a C1-4 alkylsulfonyl group, C-w alkylsulfonyloxy group or a phenyl group; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group, a C3.6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1.3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylendioxy group, a halogen atom, a C-\.2 perhalogenated alkyl group, a C1--3 halogenated alkyl group, a hydroxyl group, a C1.4 alkoxy group, a nitro, a cyano, an amino, a Cι_5 monoalkylamino group, a C2-10 dialkylamino group, a C^ alkylcarbonylamino group, a Cβ.io arylcarbonylamino group, a C1.4 alkylsulfonyl group, C1-4 alkylsulfonyloxy group or a phenyl group;
m represents 1 or 2;
and n represents 0 to 3.
2. A pyrimidone derivative or a salt thereof or a solvate thereof or a hydrate thereof according to claim 1 , wherein R1 represents an unsubstituted 4-pyridyl group.
3. A pyrimidone derivative or a salt thereof or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein R2 represents a C-M alkyl group, C1.2 alkylthio group, C1-2 alkoxy group, a trifluoromethyl group, a C5-6 cycloalkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a phenyl ring, a pyridyl ring, an indole ring, a thiophene ring; the rings being optionally substituted by 1 to 4 substituents.
4. A pyrimidone derivative which is selected from the group consisting of :
1 : 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 2 : 9-(3-phenylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 3 : 9-(2-phenylethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 4 : 9-[3-(1 H-indol-3-yl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(2-phenoxyethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(3,4-methylenedioxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1,2-a]pyrimidin-4-one; : 9-[2-(2-methoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-fluorophenoxyethyl)]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(2-chlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(4-methylphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(4-trifluoromethylphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(4-phenylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(2-methylphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(2,5-dimethoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(2-methoxyphenoxy)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(2-methoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-chlorophenoxy)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3-methoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(2-methoxyphenylmethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-phenylthioethylj-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(3,4-dimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3,4,5-trimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(phenylsulfonyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; 44 : 9-[3-(3,4-fluorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-phenylpropanoyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(4-fluorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(2,5-dimethoxyphenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(2,4-dichlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(3-fluorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(4-chlorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(3,3-dimethylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(2-cyclohexylethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one : 9-[3-(pyridin-3-yl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(4-methylsulfonyloxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(3-methylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3,3-diphenylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[4-(4-methoxyphenyl)butyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[4-(4-nitrophenyl)butyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-(2-fluorophenyl)propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-phenylprop-2-ynyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-phenylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one; : 9-[2-(2-chloro-4-fluorophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1,2-a]pyrimidin-4-one 5 : 9-(2-phenyl-2-oxo-ethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-benzyloxypropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-methylthioethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(1-naphthyl)ethylj-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(thiophen-2-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(3-trifluoromethylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[(2-(thiophen-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(2-bromophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one; : 9-(4-cyclohexylbutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one : 9-[2-(3-bromophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(4-ter-butylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(2,4,6-trimethylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-ethoxyphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(2-chloro-6-fluorophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(3-chlorophenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[2-(3-methylphenyl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-methoxybutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(3-cyclohexylpropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-[di(phenylmethyl)amino]propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one: : 9-(2-phenyl-cyclopropylmethyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(3-phenylprop-2-enyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-(2-phenyl-2-hydroxypropyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3-(4-fluorophenyl)-3-oxo-propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-(4,4,4-trifluorobutyl)-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-phenyl-3-oxo-propyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one; : 9-[3-phenyl-3-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[3,3,3-trifluoro-2-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : (R)-9-[2-phenyl-2-hydroxyethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : (S)-9-[2-phenyl-2-hydroxyethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4 -- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[1 -methyl-2-oxo-2-phenyl-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[1-methyl-2-hydroxy-2-phenyl-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one : 9-[2-(4-methylphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-chlorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-fluorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(4-phenylphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(3-methoxyphenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; : 9-[2-(2-naphthyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one* 81 : 9-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapht-2-yl)-2-oxo-ethyl]-2-pyridin-
4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;
82 : 9-[2-(3-methoxy-4,5-methylendioxyphenyl)-2-oxo-1 -methylethyl]-2-pyridin-4- yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; 83 : 9-[2-(4-methylphenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 84 : 9-[2-(1 ,1 ,4,4,-tetramethyl-1 ,2,3,4-tetrahydronapht-6-yl)-2-hydroxy-ethyl]-2- pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; 85 : 9-[2-(phenylamino)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one;
86 : 9-[2-(3-chlorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1,2-a]pyrimidin-4-one; 87 : 9-[2-(3-chlorophenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; 88 : 9-[2-(3-fluorophenyl)-2-oxo-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H- pyrimido[1 ,2-a]pyrimidin-4-one; and 89 : 9-[2-(3-fluorophenyl)-2-hydroxy-ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4/-/- pyrimido[1 ,2-a]pyrimidin-4-one; or a salt thereof or a solvate thereof or a hydrate thereof.
5. A pyrimidone derivative which is selective from the group consisting of :
1 : 1-[2-(1H-lndol-3-yl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one,
2 : 1 -[3-(phenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)- one,
3 : 1 -[3-(1 H-indol-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 f2-a]pyrimidin-
5(1H)-one,
4 : 1 -[2-(phenyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 )- one, 5 : 1-[3-(2-methylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2- a]pyrimidin-5(1 H)-one,
6 : 1-[3-(2-methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
7 : 1 -(4-phenylbutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one, 8 : 1-[3-(2-chlorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one,
9 : 1 -[3-(2,5-dimethoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1 -[3-(4-methylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[3-(3-methoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1 -[3-(3,4,5-trimethoxyphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[2-(4-fluorophenoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[2-(4-chlorophenoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 -/)-one, : 1-[3-(2,4-dichlorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[2-(phenylthio)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1 -(3-phenylpropanoyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1 -[3-(4-fluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one, : 1-[3-(3,4-difluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1/-/)-one, : 1-(2-cyclohexylethyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1H)- one, : 1-(3,3-dimethylbutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)- one. : 1-(2-phenyl-2-oxo-ethyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-
5(1H)-one, and : (S)-1-(4,4,4-trifluoro-3-hydroxybutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one. : 1-(4,4,4-trifluoro-but-2-en-1-yl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one, : 1-[3-(4-trifluoromethylphenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : (R)-1-(4,4,4-trifluoro-3-hydroxybutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, : 1-[3-(2-fluorophenyl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-
5(1H)-one, : 1-[2-(2,5-dimethoxy-phenyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, 29 : 1-[2-(phenylsulfonyl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-
5(1H)-one,
30 : 1-(4,4,4-trifluorobutyl)-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)- one, 31 : 1-[3-(pyridin-3-yl)propyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin- 5(1H)-one, 32 : 1-[2-(2-methoxy)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin- 5(1H)-one,
33 : 1-[2-(4-chloro-phenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one,
34 : 1-[2-(napht-2-yl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
35 : 1 -[2-(3-methoxy-4,5-methylendioxy-phenyl)-2-oxo-1 -methyl-ethyl]-7-pyridin-4- yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one, 36 : 1 -[2-(4-phenyl-phenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one, 3 : 1-[2-(4-methylphenyl)2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one,
38 : 1 -[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronapht-2-yl)2-oxo-ethyl]-7-pyridin-4- yl-2,3-dihydroimidazo[1 ,2-a]pyrimidin-5(1 H)-one,
39 : 1-[2-(4-fluorophenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1H)-one, and 40 : 1-[2-(3-methoxyphenyl)-2-oxo-ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1 ,2- a]pyrimidin-5(1 H)-one; or a salt thereof or a solvate thereof or a hydrate thereof.
6. A medicament comprising as an active ingredient a substance selected from the group consisting of a pyrimidone derivative according to claim 1.
7. A GSK3β inhibitor selected from the group of a pyrimidone derivative represented by formula (I) or a salt thereof or a solvate thereof or a hydrate thereof according to claim 1.
8. Use of a pyrimidone derivative according to any one of claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3β activity.
9. Use of a pyrimidone derivative according to any one of claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of a neurodegenerative disease.
10. Use of a compound according to claim 9, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies, vascular dementia; acute stroke, traumatic injuries; cerebrovascular accidents, brain cord trauma, spinal cord trauma; peripheral neuropathies; retinopathies or glaucoma.
11. Use of a compound according to any one of claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of non- insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; or cancers.
12. Use according to claim 11 wherein cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.
AU2002212249A 2000-09-01 2001-08-31 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives Ceased AU2002212249B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00402412.1 2000-09-01
EP00402410.5 2000-09-01
EP00402410A EP1184383A1 (en) 2000-09-01 2000-09-01 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP00402412A EP1184385A1 (en) 2000-09-01 2000-09-01 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
PCT/EP2001/010726 WO2002018386A1 (en) 2000-09-01 2001-08-31 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES

Publications (3)

Publication Number Publication Date
AU2002212249A1 true AU2002212249A1 (en) 2002-06-06
AU2002212249B2 AU2002212249B2 (en) 2006-11-30
AU2002212249B9 AU2002212249B9 (en) 2007-01-18

Family

ID=26073571

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1224902A Pending AU1224902A (en) 2000-09-01 2001-08-31 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
AU2002212249A Ceased AU2002212249B9 (en) 2000-09-01 2001-08-31 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU1224902A Pending AU1224902A (en) 2000-09-01 2001-08-31 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives

Country Status (16)

Country Link
US (3) US6974819B2 (en)
EP (1) EP1315731B1 (en)
JP (1) JP2004507546A (en)
KR (1) KR100800250B1 (en)
CN (2) CN1267432C (en)
AR (1) AR030587A1 (en)
AT (1) ATE269333T1 (en)
AU (2) AU1224902A (en)
CA (1) CA2419880C (en)
DE (1) DE60103909T2 (en)
DK (1) DK1315731T3 (en)
EA (1) EA005297B1 (en)
ES (1) ES2222396T3 (en)
SI (1) SI1315731T1 (en)
TR (1) TR200402342T4 (en)
WO (1) WO2002018386A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1430057T3 (en) * 2001-09-21 2006-01-16 Sanofi Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) one derivatives
US7232827B2 (en) * 2002-02-28 2007-06-19 Sanofi-Aventis Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
EP1557417B1 (en) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077363A1 (en) 2009-07-02 2011-08-24 Sanofi Aventis DERIVATIVES OF 1,2,3,4- TETRAHYDRO-PYRIMID {1,2-A} PIRIMIDIN-6-ONA, ITS PREPARATION, ITS USE IN CHEMOTHERAPY AND ITS PHARMACEUTICAL COMPOSITIONS.
KR101745028B1 (en) * 2009-07-02 2017-06-08 사노피 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof
FR2947550B1 (en) * 2009-07-02 2012-05-18 Sanofi Aventis NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
FR2947551B1 (en) * 2009-07-02 2012-05-18 Sanofi Aventis NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A) PYRIMIDIN-6-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
PT2655375E (en) 2010-12-23 2015-03-02 Sanofi Sa Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
FR2992314B1 (en) 2012-06-22 2015-10-16 Sanofi Sa NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE AND 1,2,3,4-TETRAHYDRO-PYRIMIDO {1,2-A} PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (en) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton DERIVATIVES OF PIRIMIDONA
US6004814A (en) 1998-09-25 1999-12-21 Isis Pharmaceuticals Inc. Antisense modulation of CD71 expression

Similar Documents

Publication Publication Date Title
US7566720B2 (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives
AU2002212249A1 (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
US7608624B2 (en) 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
EP1921080B1 (en) Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives
EP1295885A1 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1480981B1 (en) 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
AU2002212248A1 (en) 1-(alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7- pyridinyl-imidazo(1,2-a)pyrimidin-5(1H)-one derivatives
EP1454908A1 (en) Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
EP1454910A1 (en) Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1340761A1 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
EP1184383A1 (en) 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1184385A1 (en) 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives